Aligos Therapeutics Inc. (ALGS) carries a Roarable Rating of E (Strong Sell) with 22/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Aligos Therapeutics Inc. (NASDAQ: ALGS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $4.80 (-4.57% 1D, market cap $31.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ALGS ranks #976 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ALGS carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MGX (Metagenomi Therapeutics Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M) and ESLA (Estrella Immunopharma Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $31.7M). Among the 5-stock peer group, ALGS leads on earnings multiple (N/A) while ALGS leads on capital efficiency (-35.0% ROIC).
Per ALGS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001799448), Aligos Therapeutics Inc. generated $2.2M in revenue (-39.5% YoY), -$24.2M in net income, and -$82.5M in free cash flow against $88.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ALGS currently carries a cautious 22/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.53) and Max Pain ($5.04) forces dealer call-delta covering toward $14.37.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Aligos Therapeutics Inc. (ALGS) dropped -4.57% to $4.80, trading at 8% of its 52-week range ($3.98 – $13.69). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance UK report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -39.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ALGS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ALGS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Aligos Therapeutics Inc. (ALGS) ranks #976 by composite RQD confidence (22/100, grade E) and #800 by equity capitalization ($31.4M). Within this direct 5-issuer industry benchmark cohort, ALGS leads on earnings valuation at N/A trailing P/E, while ALGS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GNTA currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with ALGS at 22/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ALGS
ACTIVE
Aligos Therapeutics Inc. | E | 22/100 | — | — | -35.0% | -4.57% | $31.4M | Benchmark Subject |
| MGX Metagenomi Therapeutics Inc. | E | 24/100 | — | — | -35.0% | -6.01% | $31.4M | /mgx-vs-algs → |
| ESLA Estrella Immunopharma Inc. | D- | 39/100 | — | — | -35.0% | -12.27% | $31.7M | /esla-vs-algs → |
| GNTA Genenta Science S.p.A. | D | 50/100 | — | — | — | -0.27% | $29.9M | /gnta-vs-algs → |
| EVAX Evaxion A/S | D | 48/100 | — | — | — | -4.87% | $27.8M | /evax-vs-algs → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aligos Therapeutics Inc. (ALGS) reported GAAP revenue of $2.2M (-39.5% vs. FY2024 revenue of $3.6M , and -64.7% cumulative change since FY2023) , GAAP net income of -$24.2M, operating cash flow of -$82.5M, and free cash flow of -$82.5M (-2.0% YoY). On the balance sheet, ALGS closed FY2025 with $88.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.2M | -$24.2M | -$82.5M | -$82.5M | $88.5M | — |
| FY2024 (FY) | 2024-12-31 | $3.6M | -$131.2M | -$80.7M | -$80.9M | $70.1M | — |
| FY2023 (FY) | 2023-12-31 | $6.2M | -$87.7M | -$79.0M | -$79.0M | — | — |
As of 2026-11-02, Aligos Therapeutics Inc. (NASDAQ: ALGS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $4.80 (-4.57% 1D, market cap $31.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ALGS ranks #976 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ALGS carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MGX (Metagenomi Therapeutics Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M) and ESLA (Estrella Immunopharma Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $31.7M). Among the 5-stock peer group, ALGS leads on earnings multiple (N/A) while ALGS leads on capital efficiency (-35.0% ROIC).
Per ALGS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001799448), Aligos Therapeutics Inc. generated $2.2M in revenue (-39.5% YoY), -$24.2M in net income, and -$82.5M in free cash flow against $88.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ALGS last traded at $4.80 (-4.57% on volume of 23,851 shares), positioning the stock -13.20% below its 50-day simple moving average ($5.53) and -22.83% below its 200-day simple moving average ($6.22). Across its 52-week range of $3.98 to $13.69, ALGS sits at the 8.4% percentile with a 14-day RSI of 47.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.20 to $5.40).
Why ALGS Stock dropped -4.57% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ALGS carries an RQD Score of 22 out of 100, a letter grade of E, and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are scored as follows: Fundamental Cash Engine at 4/20 (ROIC -35%; FCF yield 0%), Whale/13F Flow at 5/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 5/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 5/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). The weakest pillar is Insider Conviction, and the strongest pillars are merely mid-weak, so no single area offsets the overall picture. For a prospective investor, the cash-engine score is the most consequential reading: a negative ROIC and zero FCF yield indicate the business is not currently generating returns on capital, which places the equity's upside dependent on future events rather than present earnings power. The Piotroski F-Score of 2/9 and Altman Z of 2.5 frame the balance-sheet risk as material rather than benign. Taken together, the rating characterizes the stock as a forensic-risk name and frames avoidance as the model's stated conclusion. This is an analytical reading of the provided scores, not personalized financial advice.
Aligos Therapeutics Inc. (ALGS) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the company profile. The source data does not describe its products, customers, or revenue model. The reported revenue figures in the SEC financials ($2.2M in FY 2025, $3.6M in FY 2024, $6.2M in FY 2023) indicate a declining revenue base, but the source does not identify the revenue sources.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $2.2M | $-88.0M | $-24.2M | N/A | $-82.5M | $18.3M | N/A |
| FY 2024 | $3.6M | $-89.2M | $-131.2M | N/A | $-80.9M | $37.0M | N/A |
| FY 2023 | $6.2M | $-88.1M | $-87.7M | N/A | $-79.0M | N/A | N/A |
Per the SEC financials, operating income was negative in each reported period, and free cash flow was negative in each period, while the operating margin and net margin in the market data are both -60%. The gross margin is 0%. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 2.5, and the Piotroski F-Score is 2/9. The Debt/Equity ratio is 0.5 per the rating. Reported cash declined from $37.0M in FY 2024 to $18.3M in FY 2025.
Per the recent news wire, the headlines are: an announcement that five abstracts were accepted for presentation at The Liver Meeting 2026; a TradingView report on Q3'26 earnings with a revenue estimate of 4.85M USD; a Yahoo Finance seasonal returns chart; a TradingKey complete U.S. stocks list; a Yahoo Finance Canada page for a different issuer (Adagene Inc.); and a TradingKey most-active-stocks report. All items are tagged YELLOW with impact label MARKET WIRE. The abstract acceptance is the only item describing a company-specific event; the others are aggregator or market-data pages. The Butterfly Supply-Chain Graph records no supply-chain links and no proprietary signals. Risk watch items include the negative operating margin, the decline in reported cash, and the Piotroski F-Score of 2/9.
Per the Butterfly Supply-Chain Graph, supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The source data therefore provides no upstream or downstream dependency map, no sector-correlation metrics beyond the sector classification itself, and no identified 2nd-order bottlenecks. A prospective investor should note that the absence of mapped links is a data gap, not evidence of independence from supply-chain or sector risk.
Real-time company headlines, analyst actions, and sector developments for Aligos Therapeutics Inc. (ALGS) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance UK report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Aligos Therapeutics Inc. (ALGS) market action, institutional positioning, and fundamental catalysts.
Welcome to the ALGS (Aligos Therapeutics Inc.) Roar Pit. Current RQD Composite is 22/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ALGS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Aligos Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ALGS, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $5.03 (52-wk range $3.98 - $13.69), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).